Target primacy, inference robustness, and translational causality in ferroptosis-based immunotherapy combinations

Dear Editor, We read with great interest the study by Zhou et al1, which demonstrates that isocucurbitacin B targets STAT3 to induce ferroptosis, reprogram mitochondrial metabolism, and enhance anti–PD-1 immunotherapy responses in triple-negative breast cancer using integrated multi-omics and spatial transcriptomic approaches. In the context of growing interest in ferroptosis-based therapeutic strategies and rational immunotherapy combinations to overcome resistance, this work addresses a timely and clinically relevant question. Nevertheless, several mechanistic and translational considerations warrant further clarification to strengthen causal interpretation and support the broader applicability of these findings. This study complies with the TITAN 2025 framework for transparent and ethical reporting of AI-assisted research2. While Zhou et al provide strong evidence that isocucurbitacin B binds STAT3 and suppresses its phosphorylation, whether STAT3 represents the dominant and rate-limiting driver of ferroptosis, mitochondrial rewiring, and anti–PD-1 potentiation remains insufficiently resolved. Their discovery pipeline nominates multiple credible signaling nodes beyond STAT3, yet mechanistic follow-through is largely monocentric, leaving open how much of the observed phenotype reflects on-target STAT3 biology versus scaffold-level polypharmacology typical of cucurbitacin-like compounds3. This distinction is consequential for translation, as target primacy directly informs exposure–occupancy relationships, biomarker prioritization, resistance liabilities, and rational combination design. Greater causal stringency could be achieved through orthogonal target validation and epistasis, including restoration with SH2-interface variants engineered to abrogate compound engagement, systematic assessment of activity in STAT3-null contexts with matched rescue, and proteome-scale target engagement demonstrating that STAT3 occupancy tracks with ferroptosis induction and immunotherapy sensitization. The multi-modal integration of transcriptomics, metabolomics, proteomics, and spatial profiling represents a major strength, yet it also concentrates inference risks that bear directly on translational credibility. In spatial analyses, region-of-interest ascertainment and treatment of ROIs as independent replicates can conflate within-tumor heterogeneity with between-subject effects, yielding pseudo-precision unless animals or patients are modeled as the true statistical unit with appropriate nesting4. This is not a technical footnote, as conclusions regarding reduced exhaustion, altered PD-1 axis activity, and metabolic reprogramming depend on whether significance is preserved after subject-level aggregation and hierarchical testing. Across modalities, pathway concordance may be further amplified by batch structure, analytic flexibility and multiplicity, and multiplicity when enrichment is repeatedly applied to correlated feature sets5. Explicit reporting of pre-specified contrasts, batch adjustment, and family-wise error control, together with subject-level orthogonal validation of key spatial signatures, would strengthen confidence that the reported immune and metabolic shifts reflect robust biological effects rather than analysis-dependent signal. The observed potentiation of anti–PD-1 therapy by isocucurbitacin B is translationally appealing, yet the current evidence remains largely correlative and does not define the minimal causal chain required to justify clinical extrapolation. Increased CD8⁺ T-cell infiltration and reduced exhaustion signatures are consistent with immune reinvigoration, but they do not establish whether ferroptosis constitutes the immunologically productive lesion that gates checkpoint sensitivity or whether both are parallel consequences of broader cellular stress and STAT3 pathway modulation6. Discriminating these possibilities requires necessity tests at the levels of both mechanism and effector, including CD8 depletion and targeted interruption of ferroptosis to determine whether the combination advantage is abolished7. Moreover, synergy claims in syngeneic models are inherently vulnerable to context dependence driven by baseline inflammation, tumor burden kinetics, and microbiota composition, all of which can shift checkpoint responsiveness across facilities. Demonstration of reproducibility in an additional immunocompetent model, together with reporting of key environmental covariates, would strengthen external validity and help define actionable conditions for isocucurbitacin B–based combinations in future trial design8. Collectively, clarifying target primacy, strengthening subject-level robustness of multi-modal inference, and establishing mechanism-based necessity for immunotherapy synergy would materially reinforce the translational foundation of this work. Addressing these issues would not only refine biological interpretation, but also inform biomarker development, patient selection, and rational combination strategies for ferroptosis-based immunotherapy. Such rigor is essential to ensure that promising preclinical synergy can be credibly advanced toward clinical testing and policy-relevant therapeutic decision-making.